文献速递炎症性肠病

亚临床持续性炎症作为克罗恩病进展的危险因素:一项为期2年的前瞻性真实世界研究结果

Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-12-09

DIRECT研究为注册登记的前瞻性观察性多中心研究,随访英夫利西单抗治疗的克罗恩病患者2年。180例无症状维持治疗患者中,96例发生复合终点;以连续2次粪钙卫蛋白>250 μg/g定义的持续性炎症与复合终点风险升高约3倍及更短发生时间相关。

要点

  • 连续2次粪钙卫蛋白>250 μg/g定义持续性炎症时,复合终点风险比为2.996(95%CI 1.557-5.776)。
  • 持续性炎症患者达到复合终点的中位时间缩短至11个月。
  • CRP>3 μg/mL、粪钙卫蛋白>150或>350 μg/g、双标志物或更多次数定义未改善预测能力。

核心结论

  • 以连续2次粪钙卫蛋白>250 μg/g简单定义的持续性炎症,与无症状英夫利西单抗治疗的克罗恩病患者复合终点风险显著升高及发生时间缩短相关。

研究设计与样本

  • DIRECT研究为注册登记的前瞻性观察性多中心研究,在三级医疗中心随访英夫利西单抗治疗的克罗恩病患者2年。
  • 322例DIRECT研究患者中,180例无症状、接受英夫利西单抗维持治疗的患者纳入分析。

主要发现

  • 发生复合终点者96例,其粪钙卫蛋白中位水平较高(205 [四分位距 98-515] μg/g;P = .045)。
  • 发生复合终点者CRP中位水平为2.50 [四分位距 0.80-6.00] μg/mL(P = .895)。
  • 生物标志物定义的持续性亚临床炎症患病率范围为24%至81%。
  • 以连续2次粪钙卫蛋白>250 μg/g定义时,患病率为50%,达到终点的比值比为2.996(95%CI 1.557-5.776),持续性炎症者发生结局的中位时间显著更短(11个月)。
  • 临床相关和治疗相关组分均与持续性炎症显著相关;基于CRP>3 μg/mL、粪钙卫蛋白>150 μg/g、粪钙卫蛋白>350 μg/g、双标志物(粪钙卫蛋白>250 μg/g和/或CRP>3 μg/mL)或更多次访视的定义未改善预测能力。

关键数值与推荐

  • 持续性炎症定义基于连续2次或至少3次访视的粪钙卫蛋白(>150 μg/g、>250 μg/g或>350 μg/g)或血清CRP(>3 μg/mL)浓度。
  • 复合结局包括手术、住院、新发瘘管、脓肿或狭窄以及治疗升级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Subclinical intestinal inflammation is common in Crohn's disease (CD). We aimed to explore its impact in the disease progression of infliximab-treated patients and the usefulness of fecal calprotectin (FC) and C-reactive protein (CRP) as surrogate minimally invasive biomarkers. METHODS: The registry-based, prospective, observational, multicenter DIRECT (study to investigate the correlation of fecal calprotectin with serum Drug levels and development of an antI-dRug antibodiEs among adult patients with inflammatory bowel disease reCeiving anti-TNF-alfa treatment or vedoluzimab treatment) study followed infliximab-treated CD patients for 2 years in a tertiary care setting. Persistent inflammation definition was based on FC (>150 μg/g, >250 μg/g, or >350 μg/g) or serum CRP (>3 μg/mL) concentrations over 2 consecutive or at least 3 visits. Patients were categorized according to a composite outcome reflecting disease progression that incorporated surgery; hospitalizations; new fistulae, abscess, or stricture; and treatment escalation. RESULTS: Of 322 DIRECT study patients, 180 asymptomatic, infliximab treated on maintenance regimen were included in the analysis. Patients developing the composite endpoint (n = 96) presented higher median levels of FC (205 [interquartile range, 98-515] μg/g; P = .045) but not of CRP (2.50 [interquartile range, 0.80-6.00] μg/mL; P = .895). Biomarker-defined persistent subclinical inflammation prevalence ranged from 24% to 81%. Considering FC >250 μg/g in 2 consecutive visits, prevalence was 50%, odds of achieving the endpoint were increased 3-fold (odds ratio, 2.996 [95% confidence interval, 1.557-5.776]), and time-to-outcome occurrence was significantly lower among subjects with persistent inflammation (median time: 11 months). Both clinical-related and treatment-related components were significantly associated with persistent inflammation. Definitions based on CRP >3 μg/mL, FC >150 μg/g, FC >350 μg/g, double biomarkers (FC >250 μg/g and/or CRP >3 μg/mL), or more visits did not improve predictive ability. CONCLUSIONS: Persistent inflammation, defined simply and readily by FC >250 μg/g over 2 consecutive visits, was associated with a significantly higher risk and shorter time to occurrence of a composite outcome reflecting disease progression in asymptomatic infliximab-treated CD patients.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Magro F, Magalhães D, Patita M, et al. Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years. Clin Gastroenterol Hepatol. 2021. PMID: 34896644. doi:10.1016/j.cgh.2021.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。